title: [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
abstract: We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT). A 54-year-old man with severe liver cirrhosis was diagnosed as having HCC in segment 1 and 4 of the liver, with PVTT in the left branch. After 7 courses of FAIT, the main tumor and PVTT were no longer visible on enhanced computed tomography scans. However, recurrent HCC was detected in segment 4. Subsequently, the patient was treated with transarterial chemoembolization (TACE) after confirmation of portal blood flow. At 5 years after the initial treatment, the patient is alive without further recurrence of HCC. Therefore, even if patients have HCC with PVTT in the main branch and severe liver cirrhosis, long-term survival is possible by administration of a combination of FAIT and TACE.
authors.affiliation: Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Tsuda
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tomimaru
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Akita
authors.forename: Naoki
authors.initials: N
authors.lastname: Hama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Wada
authors.forename: Koichi
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000209:etiology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000098:blood supply / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D011169:Portal Vein; D013927:Thrombosis / Q000209:etiology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D004338:Drug Combinations; D016898:Interferon-alpha; D005472:Fluorouracil